Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia

Autor: Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili, Osman Ilhan
Rok vydání: 2022
Předmět:
Zdroj: International Journal of Hematologic Oncology. 11
ISSN: 2045-1407
2045-1393
Popis: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.Hospital records between 2005 and 2018 were retrospectively reviewed.Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Hospital records of patients between 2005 and 2018 were retrospectively reviewed. Of the included 861 CP-CML patients, 31% had at least one comorbidity at diagnosis. The survival of the patients was affected by sex, cardiovascular disease status at diagnosis, and molecular (at least major) and cytogenetic (partial and complete) responses. The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
Databáze: OpenAIRE
Externí odkaz: